Evercore analyst Cory Kasimov maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and adjusts the target price from $1,250 to $1,175.
According to TipRanks data, the analyst has a success rate of 55.6% and a total average return of 19.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
The firm has adjusted its expectations for Eylea based on the launch of a generic competitor and slightly reduced the projections for Dupixent in the second half of 2024. Nonetheless, there is optimism that the stock's previous concerns have been mitigated, presenting a more favorable outlook leading up to forthcoming events.
The expectation is that a competitive product launch by a rival company is likely forthcoming due to the inability of Regeneron to obtain a delay against this event. Despite this situation, the view persists that Regeneron presents an investment opportunity in light of the recent decline in its stock price.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
